BDO’s 2018 Life Sciences Outlook

What does 2018 have in store for the life sciences industry?

BDO’s Life Sciences leaders make four predictions around VC funding, biotech M&A, milestone-based reimbursements, and Chinese biotech:

1) VC FUNDING IN THE BIOTECH SPACE WILL REMAIN IN LINE WITH 2017’S RECORD-BREAKING LEVELS.

2) BIOTECH M&A WILL BOUNCE BACK AFTER A RELATIVELY SLOW 2017.

3) EXTREMELY EXPENSIVE THERAPIES WILL BE MEASURED AND PRICED ON A PATIENT MILESTONE- BASIS, WITH REIMBURSEMENTS BASED ON THE YEARS OF LIFE THE PATIENT GAINS.

4) CHINESE BIOTECH COMPANIES WILL SEEK U.S. AND EUROPEAN REGULATORY EXPERTS IN-HOUSE.

Read our full insights around these predictions in our latest infographic, here
 

For more information or questions, please reach out to the blog authors listed below.

Don’t miss the latest BDO News and insights – subscribe here.

Blog-subscribe-ad_HC.JPG